TipRanks

5G is here. The new networks are online and expanding, and customers individual consumers, institutional users, and industrial applications are starting to take advantage of the new technology. The advantages of 5G are already well-known: faster connections, more efficient upload and download capability, lower latency, greater security. 5G tech is essential for developing the full potential of autonomous vehicles and IoT projects. How it will impact ordinary life remains to be seen.Some of Wall Streets top analysts have been taking the measure of the new network, and its probably effect on related companies and their stocks. Using TipRanks database, weve pulled up the latest data on three such stocks that the analysts have tapped for gains in the growing 5G environment. CommScope Holding (COMM)We will start with CommScope, a hardware provider for network infrastructure. The company produces antennas for building and tower installation, base stations, and outdoor wireless system power supplies. As a holding company, these CommScope products are produced and marketed by subsidiaries, to customers worldwide.The company announced last month a partnership with Nokia on a passive-active antenna platform, promising a faster 5G rollout for customers. And earlier this month, CommScope announced a contract with the city of Wyandotte, Michigan, for networking installation, including 5G, and giving the company access to over 25,000 potential customers.CommScope reported $2.17 billion in Q3 revenue, up 3% year-over-year. The Broadband segment showed 20% year-over-year growth, and the free cash flow hit $350 million. JPMorgans 5-star analyst Samik Chatterjee elaborates on CommScope forward potential: Our constructive view on shares of CommScope is led by expectations for an improving outlook for the Outdoor Wireless Segment which stands positioned to benefit from the ramp in 5G densification efforts for wireless networks, in combination with continuing resilient spending from cable/broadband networks."We expect the pace of investments in the wireline network to continue, led by bandwidth requirements to support peak usage, in addition to tailwinds stemming from initiatives such as RDOF and reclamation of satellite spectrum for 5G," the analyst added.In line with these comments, Chatterjee rates the stock an Overweight (i.e. Buy), and his $18 price target suggests a 35% upside in the coming year. (To watch Chatterjees track record, click here)Chatterjee is broadly in line with the rest of Wall Street, which has assigned COMM slightly more "buy" ratings than "holds" over the past three months -- and sees the stock growing about 19% over the next 12 months, to a target price of $15.80. (See COMM stock analysis on TipRanks)Crown Castle (CCI)The next stock on our list, Crown Castle, operates as a real estate investment trust, owning and managing cell network assets, including towers and transmitter locations. The company boasts over 40,000 towers, 70,000 operational small cells, and 80,000 miles of fiberoptic lines. Crown Castles network is part of the shared infrastructure supporting the wireless communications system in the US.The expansion of 5G networks has been good to Crown Castle, and the company has seen growth and expansion.In November, Crown Castle signed an agreement with DISH, which is looking to expand its 5G footprint. The lease agreement gives DISH rental rights on up to 20,000 towers, and includes fiber transport.Quarterly revenues have held steady between $1.4 and $1.49 billion all year, with Q3, the most recent, coming at the latter value. The company saw site rental revenue gain 4% yoy. Customer rollouts to 5G, and consequent need for additional tower sites, underlies the sound financial results.The sound quarterly results allowed the company to increase its quarterly dividend by 11%. Common share holders now receive $1.33 per common share, annualizing to $5.32 and giving a yield of 3.4%.Deutsche Bank analyst Matthew Niknam sees the DISH deal as part of an overall positive picture for Crown Castle: "CCI is poised to be the early beneficiary of multiple new industry catalysts in upcoming years, including DISH's 5G build and C-Band spectrum deployments.""Specifically, we believe its agreement with DISH for up to 20k sites puts it in a premier position to be the tower partner of choice, at least early on. Our analysis indicates DISH could easily account for 10% of CCI's Tower site leasing revenue by 2027E, with the agreement (conservatively) adding $15/share in value for CCI. Second, with ~70% of CCI's sites located in the top 100 markets, we believe its portfolio over indexes to markets most likely to see initial C-Band builds," the analyst added. To this end, Niknam rates CCI a Buy along with a $180 price target. This figure implies a 17% upside from current levels. (To watch Niknams track record, click here)So, thats Deutsche Bank's view, lets turn our attention now to rest of the Street: CCI's 3 Buys and 2 Holds coalesce into a Moderate Buy rating. Should the $170.25 average price target be met, about 11% upside could be in store. (See CCI stock analysis on TipRanks)Sierra Wireless (SWIR)Based in British Columbia, Canada, Sierra Wireless designs and manufactures wireless equipment for an international customer base. The company products include machine-to-machine and mobile computing devices for use on wireless networks, as well as modems, routers, and gateways for mobile broadband wireless. Sierra holds over 550 unique patents.Sierras focus on machine-to-machine systems make its hardware especially valuable for IoT applications. The company offers 5G capable routers and broadcast solutions for IoT networks, as well as the first 5G enabled vehicle router on the market.Turning to the financials and the stock, we see the company moving in two directions at once. Quarterly revenues have been falling this year, and Q3 came in at just $113 million far down from the $144 million reported in Q2. While the quarter was generally down, the automotive business did show a 3.6% yoy increase.The companys stock, however, has been on an upward trajectory, and with a 49% year-to-date gain has outperformed the S&P 500 index.Among the bulls is Colliers analyst Charles Anderson who calls SWIR a "5G IoT play." Anderson rates the stock a Buy along with a $20 price target. This target indicates the extent of his confidence it implies a 40% one-year upside. (To watch Andersons track record, click here)Backing his stance, Anderson writes, We like the combination here of management/Board upgrades (CEOs that led turnarounds at IDTI and LSCC recently joined the Board); business model transition toward higher margin recurring revenue; 5G product cycle exposure; and depressed valuation relative to both peers and historicals""Sierra is in the process of transforming itself from a low margin supplier of cellular connectivity hardware to a higher margin supplier of full stack cellular IoT (hardware/software/service). This is both a better business model and a more compelling offering to customers," the analyst added.All in all, Sierra has an even split among the recent reviews, 2 Buys and 2 Holds, making the analyst consensus rating a Moderate Buy. (See SWIR stock analysis on TipRanks)To find good ideas for 5G stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more:
Kamada Added to the NASDAQ Biotechnology Index - Yahoo Finance

Amarin Corporation plc (AMRN) is around the bottom of the Biotechnology industry according to InvestorsObserver. AMRN received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Amarin Corporation plc also achieved a score of 26 in the Biotechnology industry, putting it above 26 percent of Biotechnology stocks. Biotechnology is ranked 35 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Amarin Corporation plc (AMRN) stock is trading at $4.97 as of 12:11 PM on Thursday, Dec 3, a rise of $0.13, or 2.79% from the previous closing price of $4.84. The stock has traded between $4.84 and $5.06 so far today. Volume today is less active than usual. So far 3,157,880 shares have traded compared to average volume of 6,785,044 shares.

Click Here to get the full Stock Score Report on Amarin Corporation plc (AMRN) Stock.

Read more:
Where Does Amarin Corporation plc (AMRN) Stock Fall in the Biotechnology Field? - InvestorsObserver

Up-To-Date research on Biotechnology Separation Systems Market 2020-2026 :

The Reputed Garner Insights website offers vast reports on different market.They cover all industry and these reports are very precise and reliable. It also offers Biotechnology Separation Systems Market Report 2020 in its research report store. It is the most comprehensive report available on this market. The report study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Biotechnology Separation Systems Market.

The market is segmented into different sections such as: by product type, by application, by end-users, by deployment mode, and by key geography. The report then employs market breakdown and data triangulation procedures to complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments. The report on the Global Biotechnology Separation Systems Markethas been curated by analyzing the top players functioning in the market. In order to get an in-depth analysis of the market, the report carried out SWOT analysis, Porters five forces analysis, and Pestel analysis.

Request Sample Report of Global Biotechnology Separation Systems Market https://garnerinsights.com/Biotechnology-Separation-Systems-Market-Status-and-Trend-Analysis-2017-2026-COVID-19-Version#request-sample

Some of the major geographies included in the market are given below:North America (U.S., Canada)Europe (U.K., Germany, France, Italy)Asia Pacific (China, India, Japan, Singapore, Malaysia)Latin America (Brazil, Mexico)Middle East & Africa

Ask For Instant Discount @ https://garnerinsights.com/Biotechnology-Separation-Systems-Market-Status-and-Trend-Analysis-2017-2026-COVID-19-Version#discount

Components of the Biotechnology Separation Systems Market report:-A detailed assessment of all opportunities and risk in this Market.-Recent innovations and major events-A comprehensive study of business strategies for the growth of the Biotechnology Separation Systems leading market players.-Conclusive study about the growth plot of Biotechnology Separation Systems Market for the upcoming years.-Understanding of Biotechnology Separation Systems Industry-particular drivers, constraints and major micro markets in detail.-An evident impression of vital technological and latest market trends striking theMarket.

The objectives of the study are as follows:

View Full Report @ https://garnerinsights.com/Biotechnology-Separation-Systems-Market-Status-and-Trend-Analysis-2017-2026-COVID-19-Version

Contact UsKevin ThomasEmail: sales@garnerinsights.comContact No:+1 513 549 5911 (US) | +44 203 318 2846 (UK)

Other Reports:

Impact-Of-Covid-19-On-Curtain-Led-Screen-Market-Is-Expected-To-Grow-At-An-Active-Cagr-By-Forecast-To-2024-Top-Players-Daktronics-Barco-Mitsubishi-Electric-Absen/

Impact-Of-Covid-19-On-Displayport-Connectors-Market-Is-Expected-To-Grow-At-An-Active-Cagr-By-Forecast-To-2024-Top-Players-Molex-Mouser-Electronics-Te-Connectivity-Allekabels/

Impact-Of-Covid-19-On-Draw-Wire-Displacement-Sensors-Market-Is-Expected-To-Grow-At-An-Active-Cagr-By-Forecast-To-2024-Top-Players-Asm-Sensor-Baumer-Group-Siko-Bei-Sensors/

Impact-Of-Covid-19-On-Electric-Curtains-Market-Is-Expected-To-Grow-At-An-Active-Cagr-By-Forecast-To-2024-Top-Players-Hunterdouglas-Somfy-Budget-Blinds-Silent-Gliss/

Impact-Of-Covid-19-On-Gfci-Receptacles-Market-Is-Expected-To-Grow-At-An-Active-Cagr-By-Forecast-To-2024-Top-Players-Hubbell-Leviton-Pass-Seymour-Eaton/

Read the rest here:
Impact of Covid-19 on Biotechnology Separation Systems Market 2020 | Top Business Growing Strategies, Technological Innovation and Emerging Trends of...

Thats the philosophy of Felix Paul Joe and preferably the biggest explanation one can have for his unflinching crusade in the field of biotech research. Felix founded GeneX India Bioscience Pvt. Ltd. in 2004 but, the journey before it prepared him for everything that came next.

After earning a Masters in Life Science and Post Graduate Diploma in Business Administration from the University of Madras and Madras Productivity Council, Felix was all set to create his own path in biotechnology. But, revolution is a way paved stone by stone. Before realizing his passion and dream to become an entrepreneur, Felix completed a nine-year run in different biotech companies. As a National Sales & Product Manager, he embarked on a journey that shaped his understanding of what the industry is and what it needs.

He attended a plethora of application training on varied subjects like molecular biology, cellular microscopy, interphase chromosome profiling and Proteomics. His learnings from these teachings formed a crucial part of his ventures growth model in the later years. He also completed exclusive product training and lab sessions at many international labs and forums during his days as a manager. Working with many Centres for Excellence labs across India, Felix perceived the need for a bridge between the Indian and global standards.

In 2004, when Felix established GeneX India Bioscience, the company only started as a distributor of cell culture products. Molecular biology and biotechnology were then added to widen the spectrum. Today, the company focusses in the fields of bio-science research institutes, molecular diagnostic labs, biopharmaceutical R&D, biotech contract research and development centres.

Over the years, the organization created a line of products and solutions, namely Cell Biology, Real-Time PCR, Epigenetics, Next Generation Sequencing and Protein Biology. The private company is a full-fledged service provider for cell biology, flowcytometry and proteomics. As envisioned by Felix, GeneX also acts as a middleman nurturing quality products, scientific and technical support between biotech solution providers in Europe, USA, UK and Indian researchers who work across the relevant fields.

GeneX India has an experienced team of 33 scientifically-qualified professionals who possess the capability to market, conduct workshops, seminars. They cumulatively provide solutions to scientists and research scholars, helping them complete their research. The team works in constant collaboration mode to ensure a zero-defect product and service range. The stringent quality standard and client-centric approach have made the enterprise synonymous to the word biotech all across the world.

Following this unprecedented rise, GeneX India has been recognized for its efforts via major accolades like the Biotech Excellence and the APJ Abdul Kalam Excellence Award. The CEO magazine also noted GeneX as one of the 25 fastest growing biotechnology companies in India recently. Moreover, Felix himself has been the recipient of multiple national and international awards such as the Mahatma Gandhi Samman at the House of Commons, UK.

Even during the COVID pandemic, Felix and his company have been dedicated to aiding ICMR approved testing labs and kit manufacturers. Vaccine research labs and producers are being helped in complete sync too.

As the future entails, Felix is now set on scaling the firm to global benchmarks and giving Indian research the world stage it deserves. A plan to support the bioprocess and vaccine development has been put in place as well. He also aims to produce affordable molecular diagnostic kits using the latest technology like the CRISPR Cas9 Genome editing tool. A Contract Research Lab that acts as a high-end core facility with its primary focus on Genomics and DNA sequencing for molecular diagnostics is also in the works. The end goal is to provide services to biotech researchers and in turn, become a parallel economic solution provider for the high throughput, time-bound turnkey biotech projects and diagnostic labs.

A reputable part of the significant science congresses across the country, Felix has always had the vision to create a sustainable future for the world. He has a strong conviction that the firms business model should make a profound and positive impact on the lives of all the researchers it touches. His every step has been towards building his own pathway that treads towards this purpose.

Go here to see the original:
Cell Biology, Molecular Biology, Biotechnology And The Man Who Is Connecting It All: Felix Paul Joe - Outlook India

The recently added report namely Global Biotechnology-Based Chemical Market Size, Status and Forecast 2020-2026 presents comprehensive details on market by segmenting the total market based on the product types, vital players, applications, and other competitors involved in the international market. The report throws light on factors boosting the global Biotechnology-Based Chemical markets growth and giving a positive push to succeed in the market. The report evaluates industry size, regional spectrum, and revenue estimates of the business. The study explores major challenges as well as the latest growth strategies implemented by significant players in the industry. Also, the major opportunities available in the market are highlighted in the report.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Competitive Analysis:

The report identifies various key manufacturers in the global Biotechnology-Based Chemical market. A basic significance of the entire product developed by prominent manufacturers as well as the product application scope has been delivered in the report for 2020 to 2025 forecast period. The study comprises information pertaining to the companies, based on their market position currently, as well as significant highlights about the sales accumulated by the manufacturers. Alongside the industry share that these companies hold has also been given. The companys profit margins along with the price models have been elucidated as well.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/20865/request-sample

The report offers a detailed scope of the global Biotechnology-Based Chemical market covering essential data about the recent market status and prime manufacturers. This study unfolds the deep appraisal of the market size, growth rates, price, industry dynamics as well as various other parameters including product supply ratio, profit margin, demand analysis, and detailed cost structure for the industry.

Market major companies operated into: Queenslands world-class agriculture industry, Sarnia-Lambton Research, UK and Norway business funding agencies, Technology Strategy Board (TSB), Innovation Norway,

Product type can be split into: Bio-pharma, Agri-biotech, Bio-informatics and, Bio-services, Others,

The application can be split into: Food and beverages, Agriculture, Fuel, Energy, Animal feed, Pharmaceuticals and nutrition, Paper and pulp, Cosmetics and toiletries, Plastics and fibres, Other

Regional Segment Analysis:

This report focuses on volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall global Biotechnology-Based Chemical market size by analyzing historical data and future prospects. The data is not just restricted to regions but the country-wise market analysis is also included. Regionally, this report focuses on several key regions: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-biotechnology-based-chemical-market-size-status-and-forecast-20865.html

How Does Our Report Help You?

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

Global Photobooks Market 2020 Sales Channels, Technology and Production Analysis, Business Growth by 2026

Global Veterinary Rapid Test Market 2020 Regulatory Framework, Market Strategies and End-User Applicants by 2026

Global Insert Ceramic Ball Market 2020 Report Reviews on Key Manufacturers, Regional markets, Application and Segmentation by 2026

Global Polypropylene Alloy Market 2020 Industry Analysis, Type and Application, Key Players, Regions, Forecast by 2026

Global Snap Action Switches Market 2020 Research Study with Trends and Opportunities to 2026 Impact of COVID-19

Global Silicon Germanium Devices Market 2020 Size, Market Share, Key Players, Segmentation Development and Forecast by 2026

View original post here:
Global Biotechnology-Based Chemical Market 2020 Future Trend, Business Strategies, Revenue Value, Comprehensive Analysis and Forecast by 2026 -...

FLORHAM PARK, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

Third Quarter 2020 and Recent Business Highlights

Successfully raised approximately $19 million via a public offering of common stock.

Initiated VERSATILE-002, a Phase 2 trial of PDS0101, our investigational drug candidate, in combination with standard of care KEYTRUDA for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.

Initiated a Phase 2 study of PDS0101 in combination with standard of care chemoradiotherapy at the MD Anderson Cancer Center for treatment of locally advanced cervical cancer.

Continued development of PDS0103 in partnership with the National Cancer Institute.

Advanced co-development program with Farmacore with plans to move the PDS0203 COVID-19 vaccine into clinical development with the support of the Brazilian government.

Expanded Board of Directors with appointment of preeminent oncologist, Otis Brawley, M.D.

As a result of our teams dedicated efforts during the third quarter and our clinical partnerships with leading institutions in immuno-oncology, today PDS0101 is being evaluated in three phase 2 clinical trials for multiple HPV-associated cancers, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. Furthermore, the successful equity raise we completed in August strengthened our balance sheet, ensuring we can continue to progress the clinical development of our oncology programs as well as expand both our oncology and infectious disease programs despite the challenges posed by the COVID-19 pandemic.

Third Quarter 2020 Financial Review

Story continues

For the third quarter of 2020, net loss was approximately $3.9 million, or $0.23 per basic share and diluted share, compared to a net loss of approximately $5.8 million, or $1.10 per basic share and diluted share for the third quarter of 2019.

Research and development expenses totaled approximately $2.1 million for the third quarter of 2020, compared to approximately $1.8 million for the same period in 2019, an increase of 12%. The increase was primarily attributable to an increase of $0.1 million in technical operations (manufacturing) and $0.3 million in clinical studies, offset by a decrease of $0.1 million in professional fees and $0.1 million in regulatory expenses.

For the third quarter of 2020, general and administrative expenses were approximately $1.8 million compared with approximately $3.0 million during the third quarter of 2019, a decrease of 40%. The decrease was primarily attributable to a decrease of $0.2 million in salary and benefits, $0.1 million in facilities and office expense, $0.3 million in insurance expense, $0.6 million in professional fees, and $0.1 million in legal fees offset by an increase of $0.1 million in licenses, taxes and fees.

Total operating expenses for the third quarter of 2020 were approximately $3.9 million, compared to total operating expenses of approximately $5.8 million during the same period of 2019, a decrease of 33%.

As of September 30, 2020, the Companys cash balance was approximately $33.5 million.

Conference Call and Webcast

The conference call is scheduled to begin at 8:00 am ET on Thursday, November 12, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13712632.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project, intend, forecast, guidance, outlook and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the Companys dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Companys operations or require the Company to relinquish rights to the Companys technologies or product candidates; the Companys limited operating history in the Companys current line of business, which makes it difficult to evaluate the Companys prospects, the Companys business plan or the likelihood of the Companys successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101 and other Versamune based products; the future success of such trials; the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and other Versamune based products and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved; the timing of and the Companys ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Companys product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Jacob GoldbergerCG CapitalPhone: +1 (404) 736-3841Email: jacob@cg.capital

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

September 30, 2020

December 31, 2019

ASSETS

(unaudited)

Current assets:

Cash and cash equivalents

$

33,468,935

$

12,161,739

Prepaid expenses and other

373,395

2,308,462

Total current assets

33,842,330

14,470,201

Property and equipment, net

9,345

21,051

Operating lease right-to-use asset

593,580

Total assets

$

34,445,255

$

14,491,252

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES

Current liabilities:

Accounts payable

$

1,559,591

$

1,197,720

Accrued expenses

1,222,773

1,097,640

Restructuring reserve

498,185

Operating lease obligation - short term

116,240

Total current liabilities

2,898,604

2,793,545

Noncurrent liability:

Operating lease obligation - long term

521,692

STOCKHOLDERS' EQUITY

Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2020 and December 31, 2019, 22,261,619 shares and 5,281,237 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

7,346

1,742

Additional paid-in capital

70,775,892

40,633,670

Accumulated deficit

(39,758,279

)

(28,937,705

)

Total stockholders' equity

31,024,959

11,697,707

Total liabilities and stockholders' equity

$

34,445,255

$

14,491,252

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Read more:
PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update - Yahoo Finance

Biotechnology Separation Systems Market Scenario 2020-2028:

The Global Biotechnology Separation Systems market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2028. On the basis of historical data, Biotechnology Separation Systems market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Biotechnology Separation Systems industry is likely to appear as a commendable platform for emerging Biotechnology Separation Systems market investors.

This Biotechnology Separation Systems Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Get Sample Report: https://grandviewreport.com/sample/75090

The complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. This Market report covers technical data, manufacturing plants analysis, and raw material sources analysis of Biotechnology Separation Systems Industry as well as explains which product has the highest penetration, their profit margins, and R&D status. The report makes future projections based on the analysis of the subdivision of the market which includes the global market size by product category, end-user application, and various regions.

Topmost Leading Manufacturer Covered in this report:Danaher, Thermo Fisher Scientific, BD, Merck, GE Healthcare, Agilent, Sysmex, Alfa Wassermann, Shimadzu, Sartorius Stedim Biotech, Illumina, Waters, Novasep, 3M Purification, Affymetrix, Bio-Rad Laboratories, Alfa Laval, PerkinElmer, Repligen, Hitachi Koki

Product Segment Analysis: Membrane Filtration, Liquid Chromatography, Centrifuge, Electrophoresis, Flow Cytometry

Application Segment Analysis:Commercial, Scientific Research

Get Discount @ https://grandviewreport.com/discount/75090

Regional Analysis For Biotechnology Separation SystemsMarket

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Market Synopsis:The market research report consists of extensive primary research, as well as an in-depth analysis of the qualitative and quantitative aspects by various industry specialists and professionals, to gain a deeper insight into the market and the overall landscape.

The objectives of the report are:

To analyze and forecast the market size of Biotechnology Separation SystemsIndustry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://grandviewreport.com/industry-growth/Biotechnology-Separation-Systems-Market-75090

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the Biotechnology Separation Systems markets.

Contact Us:Grand View Report(UK) +44-208-133-9198(APAC) +91-73789-80300Email : [emailprotected]

Read more:
Biotechnology Separation Systems Market Analysis highlights the Impact of covid-19 (2020-2028) | Danaher, Thermo Fisher Scientific, BD, Merck, GE...

Pharmaceutical & Biotechnology Environmental Monitoring Market 2020: Latest Analysis

Chicago, United States:- Global Pharmaceutical & Biotechnology Environmental Monitoring Market reports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global Pharmaceutical & Biotechnology Environmental Monitoring market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Pharmaceutical & Biotechnology Environmental Monitoring market through leading segments. The regional study of the global Pharmaceutical & Biotechnology Environmental Monitoring market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Pharmaceutical & Biotechnology Environmental Monitoring market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Pharmaceutical & Biotechnology Environmental Monitoring Market report offers a detailed Outlook and future prospects of the Industry. The Pharmaceutical & Biotechnology Environmental Monitoring Market report includes various topics like market size & share, Product types, applications, key market drivers & restraints, challenges, growth opportunities, key players, competitive landscape.

Top Players of Pharmaceutical & Biotechnology Environmental Monitoring Market are Studied: Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco, RMONI, Amphenol Advanced Sensors, Vaisala

Download Free Sample PDF (including full TOC, Tables, and Figures) of Pharmaceutical & Biotechnology Environmental Monitoring Market Research 2020-2026:- @

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Pharmaceutical & Biotechnology Environmental Monitoring market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Pharmaceutical & Biotechnology Environmental Monitoring market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

NOTE:Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Pharmaceutical & Biotechnology Environmental Monitoring Market which would mention How the Covid-19 is Affecting the Pharmaceutical & Biotechnology Environmental Monitoring Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Pharmaceutical & Biotechnology Environmental Monitoring Players to Combat Covid-19 Impact.

Environmental monitoring during pharmaceutical and biopharmaceutical production is crucial for ensuring the safety of formulated drug products. While requirements for the control of both viable (living microorganisms) and non-viable particles (e.g. dust, hair, etc.) and other contaminants (i.e. trace metals, volatiles, etc.) for aseptic manufacturing operations are more extensive than those for non-sterile processes, the quantity of samples that must be analyzed and the amount of data generated can be daunting regardless of the final drug form, particularly for global companies with multiple production facilities.

The report forecast global Pharmaceutical & Biotechnology Environmental Monitoring market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation.The report offers detailed coverage of Pharmaceutical & Biotechnology Environmental Monitoring industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Pharmaceutical & Biotechnology Environmental Monitoring by geography. The report splits the market size, by volume and value, on the basis of application type and geography.First, this report covers the present status and the future prospects of the global Pharmaceutical & Biotechnology Environmental Monitoring market for 2015-2024.And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].At the same time, we classify Pharmaceutical & Biotechnology Environmental Monitoring according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.Finally, the report provides detailed profile and data information analysis of leading Pharmaceutical & Biotechnology Environmental Monitoring company.

Our exploration specialists acutely ascertain the significant aspects of the global Pharmaceutical & Biotechnology Environmental Monitoring market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Pharmaceutical & Biotechnology Environmental Monitoring market situation. In this Pharmaceutical & Biotechnology Environmental Monitoring report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Pharmaceutical & Biotechnology Environmental Monitoring report comprises of primary and secondary data which is exemplified in the form of pie outlines, Pharmaceutical & Biotechnology Environmental Monitoring tables, analytical figures, and reference diagrams. The Pharmaceutical & Biotechnology Environmental Monitoring report is presented in an efficient way that involves basic dialect, basic Pharmaceutical & Biotechnology Environmental Monitoring outline, agreements, and certain facts as per solace and comprehension.

Segmentation by Application: Pharmaceutical IndustryBiotechnology IndustryAcademic & Research Institutes

Segmentation by Type: Monitoring EquipmentMediaSoftwareMicrobiology Services

The Essential Content Covered in the GlobalPharmaceutical & Biotechnology Environmental Monitoring Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Regional Coverage: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global Pharmaceutical & Biotechnology Environmental Monitoring market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

Get Full Customize report or for any Special Discount [emailprotected] @ https://www.reporthive.com/request_customization/2501701

Table of Contents

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Pharmaceutical & Biotechnology Environmental Monitoring market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Pharmaceutical & Biotechnology Environmental Monitoring market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the global Pharmaceutical & Biotechnology Environmental Monitoring market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Pharmaceutical & Biotechnology Environmental Monitoring market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Market by Application: Here, various application segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Pharmaceutical & Biotechnology Environmental Monitoring market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Pharmaceutical & Biotechnology Environmental Monitoring market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2501701

Why Go For Report Hive Research?Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Pharmaceutical & Biotechnology Environmental Monitoring Market Forecast, Pharmaceutical & Biotechnology Environmental Monitoring Market Trends, Pharmaceutical & Biotechnology Environmental Monitoring Market Research, Pharmaceutical & Biotechnology Environmental Monitoring, Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis, Pharmaceutical & Biotechnology Environmental Monitoring application, Pharmaceutical & Biotechnology Environmental Monitoring Market CAGR Competitive Landscape, Pharmaceutical & Biotechnology Environmental Monitoring Market Growth

Get in Touch with Us :

Report Hive Research

Website: https://www.reporthive.com

Email: [emailprotected]

Speak to Research Analyst: +1-312-604-7084

See more here:
Covid-19 Impact On Pharmaceutical & Biotechnology Environmental Monitoring Market : Growth, Segmentation Analysis By Application And Regions To...

U.S. biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shownpositive results inseverely ill patients

Vancouver, WACytoDyn Inc. (CytoDyn) a late-stage biotechnology companydeveloping leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announcedit is currently accepting only 155 more candidates across the country for its Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19.

CytoDyn is currently enrolling COVID-19 patients in its Phase 2b/3 clinical trial in at least 13 hospitals in nine states (California, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon and Texas). Please visit the Companys website atwww.cytodyn.com. The sites currently enrolling patients are listed on the home page under Clinical Trial Enrollment, then click on COVID-19 Severe or Critical in the drop-down screen. Please visit the website frequently, as the list of hospitals is updated on a regular basis.

CytoDyn has already enrolled 235 patients in its trial, and the Data Safety Monitoring Committee (DSMC) recently recommended CytoDyn continue its study without modification to achieve its primary endpoint, based on the results the DSMC observed so far.

The DSMC also added that it will look at the unblinded data again, once an additional 58 patients are enrolled.

We are very encouraged the DSMC recommended we continue our trial without modification, said Nader Pourhassan, Ph.D., President and CEO of CytoDyn.We believe this result, combined with the promising data already demonstrated with emergency INDs in over 60 severe and critical COVID-19 patients, is an indicator of positive data.

Its our hope this means our study is not only proving to be safe, but effective. If it wasnt, the DSMC would have stopped our trial or requested modifications.But instead, the DSMC recommended we continue our study without modification, and indicated it would look at the unblinded data once we are 75% enrolled.This, to us, is a very strong signal of positive data, added Pourhassan.

The recovery of a young woman in California provides some hopeful evidence of the effectiveness of leronlimab, Pourhassan said. She had contracted COVID-19 and was in the hospital on a ventilator. Within 24 hours after receiving a single injection of leronlimab, the amount of oxygen she needed started to drop, and 2 days later, she was able to be removed from her ventilator and later, sent home. She believes our drug saved her life.

We are optimistic and look forward to the completion of our study, or possible early evaluation to warrant an Emergency Use Authorization (EUA) from the FDA, Pourhassan concluded.

About Coronavirus Disease 2019

CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S.; an interim analysis on the first 195 patients was conducted mid-October.

CytoDyn is currently enrolling patients in its Phase 2b/3 COVID-19 trial for patients with severe-to-critical indications in at least 13 hospitals and clinics across the U.S., which are identified in this press release and on the Companys website under the Clinical Trial Enrollment section of the homepage.

About Leronlimab (PRO 140)

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells.CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA met telephonically with Company key personnel and its clinical research organization and provided written responses to the Companys questions concerning its recent Biologics License Application (BLA) for this HIV combination therapy in order to expedite the resubmission of its BLA filing for this indication.

CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.

CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, including for patients with COVID-19, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain emergency use authorization or regulatory approval for leronlimab for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results,(ii) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (iii) the market for, and marketability of, any product that is approved, (iv) the sufficiency of the Companys cash position, (v) the Companys ability to raise additional capital to fund its operations, (vi) the Companys ability to meet its debt obligations, if any, (vii) the Companys ability to enter into partnership or licensing arrangements with third parties, (viii) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (ix) the Companys ability to achieve approval of a marketable product, (x) the design, implementation and conduct of the Companys clinical trials, ((xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this release.

(Visited 2,352 times, 2,352 visits today)

Visit link:
US biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shown positive results in severely ill...

Oct. 23, 2020 12:00 UTC

Marc Schegerin, MD and Sapna Srivastava, PhD join as new board members and Micah Zajic as Chief Business Officer

WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotech (SQZ), a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions, today announced the appointments of Marc Schegerin, MD and Sapna Srivastava, PhD to its board of directors as well as Micah Zajic as chief business officer.

Its an honor to have Marc and Sapna join our board of directors. Their senior leadership experience in the biotech and healthcare fields will be invaluable as we continue to execute on our long-term vision to create novel, impactful cell therapies for patients in need, said Armon Sharei, PhD, founder and chief executive officer of SQZ. In addition, I am pleased to welcome Micah to our team during this pivotal time in our evolution. His diverse experience in biotech and corporate finance will provide us with strategic insight and strong leadership as we continue to develop our pipeline and manage our strategic partnerships.

Dr. Schegerin joins the SQZ board of directors with a wealth of experience in the healthcare and financial industries. He is currently chief financial officer and chief operating officer at Morphic Therapeutics. Before joining Morphic, Dr. Schegerin served as chief financial officer, and head of strategy at ArQule, until its acquisition by Merck for $2.7 billion. Prior to ArQule, Dr. Schegerin served in various senior healthcare investment banking roles at CitiGroup, Bank of America Merrill Lynch, and Goldman Sachs. Dr. Schegerin has also held industry management roles at Biogen and Sage Therapeutics. Dr. Schegerin earned his MD from Dartmouth Medical School (Payson/Hampers Scholar) and his MBA from the Tuck School of Business at Dartmouth (Don Wilson, III scholar).

Dr. Srivastava was most recently the chief financial and strategy officer for Abide Therapeutics, which was acquired by Lundbeck. Previously Dr. Srivastava served as chief financial and strategy officer for Intellia, where she played an integral role in launching the companys financial operations and strategic direction and spearheading its initial public offering. Additionally, Dr. Srivastava has nearly 15 years of experience as a research analyst in the biotechnology sector, which includes her work at Goldman Sachs, Morgan Stanley, ThinkEquity Partners, and JP Morgan. Dr. Srivastava also has experience as an independent board member and advisor to several biotechnology companies and non-profit organizations. Dr. Srivastava received her PhD in neuroscience from New York University and her bachelors from St. Xavier's College in India.

We are thrilled to have both Dr. Schegerin and Dr. Srivastava join our board, said Amy Schulman, chair of the board of directors at SQZ. Both have diverse experience within the biotechnology industry and have demonstrated success across the spectrum of both finance and healthcare, which bolsters our boards expertise as we navigate the companys next phase of growth.

Micah Zajic joins SQZ as chief business officer with over 15 years of experience in biotech and corporate development. He most recently served as vice president of corporate development at MeiraGTx and was responsible for all business development activities. Prior to MeiraGTx, Mr. Zajic worked at Alexion Pharmaceuticals, where he was primarily focused on the evaluation and execution of external partnerships, license agreements, and acquisitions. He started his career in Morgan Stanley's Global Capital Markets and Healthcare Investment Banking Group. Mr. Zajic received his bachelors in economics from Georgetown University.

About SQZ Biotech

SQZ Biotech is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the unique ability to deliver multiple materials into many patient cell types to engineer what we believe to be an unprecedented range of potential therapeutics for a range of diseases. SQZ has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of pre-conditioning and lengthy hospital stays. Our goal is to use the SQZ approach to establish a new paradigm for cell therapies. The first therapeutic applications leverage SQZs ability to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. For more information please visit http://www.sqzbiotech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005055/en/

Read more:
SQZ Biotech Strengthens Board of Directors and Appoints New Chief Business Officer - BioSpace

Cardiff Oncology Inc (CRDF) is around the top of the Biotechnology industry according to InvestorsObserver. CRDF received an overall rating of 89, which means that it scores higher than 89 percent of all stocks. Cardiff Oncology Inc also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cardiff Oncology Inc (CRDF) stock is trading at $13.30 as of 11:34 AM on Thursday, Oct 22, a gain of $1.28, or 10.65% from the previous closing price of $12.02. The stock has traded between $12.50 and $13.41 so far today. Volume today is below average. So far 427,977 shares have traded compared to average volume of 3,743,546 shares.

Click Here to get the full Stock Score Report on Cardiff Oncology Inc (CRDF) Stock.

Continue reading here:
Is Cardiff Oncology Inc (CRDF) a Winner in the Biotechnology Industry? - InvestorsObserver

DUBLIN, Oct. 20, 2020 The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report has been added to ResearchAndMarkets.coms offering.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key benefits

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in joint venture partnerships2.1. Introduction2.2. Definition of joint venture deals2.3. Success factors for joint venture partnerships2.4. When joint venture partnerships can be useful2.5. Attributes of joint venture partnerships2.6. Aligning partners to make the joint venture work2.7. Trends in joint venture partnerships since 20142.7.1. Joint venture dealmaking by year, 2014 to 20202.7.2. Joint venture dealmaking by stage of development 2014 to 20202.7.3. Joint venture dealmaking by industry sector 2014 to 20202.7.4. Joint venture dealmaking by therapy area, 2014 to 20202.7.5. Joint venture dealmaking by technology type, 2014 to 20202.7.6. Joint venture dealmaking by most active company, 2014 to 20202.8. The future of joint venture partnerships

Chapter 3 Overview of joint venture deal structure3.1. Introduction3.2. Joint venture agreement structure3.3. Example joint venture agreements3.3.1. Case study 1: Agila Specialties Pfenex3.3.2. Case study 2: Dance Biopharm Harmony Asset

Chapter 4 Leading joint venture deals4.1. Introduction4.2. Top joint venture deals by value

Chapter 5 Top 25 most active active joint venture dealmakers5.1. Introduction5.2. Top 25 most active joint venture dealmakers

Chapter 6 Joint venture deals including contracts directory6.1. Introduction6.2. Joint venture deals with contracts 2014 to 2020

AppendicesAppendix 1 Joint venture dealmaking by companies A-ZAppendix 2 Joint venture dealmaking by industry sectorAppendix 3 Joint venture dealmaking by stage of developmentAppendix 4 Joint venture dealmaking by therapy areaAppendix 5 Joint venture dealmaking by technology typeAppendix 6 Joint venture referencesAppendix 7 ResourcesAppendix 8 Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/b8myyj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Latest Joint Venture Agreements Announced in the Pharmaceutical, Biotechnology and Diagnostic, 2020 - Virtual-Strategy Magazine

IntelGenx Technologies Corp. (IGXT) is around the top of the Biotechnology industry according to InvestorsObserver. IGXT received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. IntelGenx Technologies Corp. also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

IntelGenx Technologies Corp. (IGXT) stock is trading at $0.54 as of 9:39 AM on Monday, Jun 21, a drop of -$0.02, or -3.53% from the previous closing price of $0.55. The stock has traded between $0.53 and $0.58 so far today. Volume today is less active than usual. So far 81,071 shares have traded compared to average volume of 260,291 shares.

Click Here to get the full Stock Score Report on IntelGenx Technologies Corp. (IGXT) Stock.

See more here:
Is IntelGenx Technologies Corp. (IGXT) a Leader in the Biotechnology Industry? - InvestorsObserver

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Agricultural Biotechnology market.

Trusted Business Insights presents an updated and Latest Study on Agricultural Biotechnology Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Agricultural Biotechnology market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Agricultural Biotechnology Market Size, Market Research and Industry Forecast Report, 2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Global Agricultural Biotechnology Market

The global agricultural biotechnology market size was estimated at USD 89.89 billion in 2018 and is projected to grow at a CAGR of 7.07% during the forecast period. An increase in demand for new breeding techniques is expected to propel the market growth. This is supplemented by increasing penetration of biotechnology tools to create or modify traits of organisms-including plants, animals, and microbes-with respect to color, yield, or size.Biotechnology tools are gaining significant demand across agricultural applications. These include tissue culture and micropropagation, marker-assisted selection or molecular breeding, genetically modified crops & genetic engineering, molecular diagnostic technologies, and conventional plant breeding.

A rise in the adoption of Genetically Modified (GM) crops globally is expected to drive the market throughout the forecast period. This is because genetic modification allows the production of feed and food crops with enhanced characteristics such as high nutritional value, high yield, enhanced food-processing qualities, and resistance against diseases and insects. In many countries, GM crops have been adopted rapidly, and the market for insect-resistant, herbicide-tolerant GM seeds is among the growing sectors of the agricultural industry.According to the estimates of International Service for the Acquisition of Agri-biotech Applications (ISAAA), 2.15 billion hectares of biotechnology crops have been commercially grown from 1996 to 2016. This includes 0.34 billion hectares of biotechnology cotton, 1.04 billion hectares of biotechnology soybean, 0.13 billion hectares of biotechnology canola, and 0.64 billion hectares of biotechnology maize. These products contribute to a major portion of fiber, feed, fuel, and food consumption globally.

Application Insights of Global Agricultural Biotechnology Market

The agricultural biotechnology market is classified into six segments based on application, namely vaccine development, transgenic crops & animals, antibiotic development, nutritional supplements, flower culturing, and biofuels. Transgenic crops & animals segment generated the highest revenue in 2018 while vaccine development is estimated to witness fastest growth than other applications.Agricultural biotechnology has helped in livestock as well as crop enhancement via incorporating advanced tools. Agriculture-integrated biotechnology finds vast applications across tissue culture, micropropagation, embryo transfer, cloning, and artificial insemination among others. Biotechnology tools have been applied successfully in micropropagation of disease-free plants, improving aluminum tolerance, crop fortification, and genetic modification in crops.OrganismType Insights of Global Agricultural Biotechnology Market

Agricultural biotechnology involves the use of a broad range of modern techniques to develop innovative products with enhanced quality traits. Conventional breeding techniques have been adopted largely to carry out alterations in plant and animal genomes. In addition, advancements in the field of genetic engineering have enabled controlling of genetic changes induced into the organism.Advanced biotechnology tools have enabled professionals to incorporate new genes from one species to another unrelated species targeting towards the optimization of agricultural production or manufacturing valuable pharmaceutical compounds. The most common subjects of genetic engineering include farm animals, crops, and soil bacteria.

The global agricultural biotechnology market is classified into three segments based on the organism: plants, animals, and microbes. The plants segment has generated the largest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. Whereas animals segment is expected to grow at the fastest CAGR in the coming years. Each of the segments of organism outlook is further classified into three segments based on techniques; conventional techniques, established genetic modification, and new breeding techniques.

Regional Insights of Global Agricultural Biotechnology Market

North America dominated with the largest revenue share in 2018, owing to its wide range of agro-climatic zones and crops, along with a large global Genetically Modified (GM) planted area. In this region, the U.S. and Canada together represent around 50% of the global GM area and around 10% global planted area. Major crops cultivated in around 70% of the cultivated area of North America include corn, soybean, and wheat, followed by alfalfa, cotton, canola, & barley. Moreover, North America is a net exporter of agricultural products with around 30% production of corn, soybean, and wheat globally.Whereas, Asia Pacific is expected to grow at the fastest pace during the forecast period. This region is characterized by the presence of several with different political & economic systems, cultural backgrounds, and languages. Within these, the agricultural industry varies from the adoption of high technical standards in Japan to basic systems in India.Asia Pacific serves as a lucrative market as the region occupies nearly 40% of the global cropped area (nearly 600 million hectares). The region is also characterized by the importance of rice crop (except Australasia), and the predominance of smallholders. Rice is available at highly subsidized rates across Asia and food security is a major concern for local governments in most of its developing economies. The region holds nearly 90% of the total crop area for rice, with 20% and 28% in China and India respectively.Agricultural Biotechnology Market InsightsKey players in the market include KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, and Bayer AG. These companies are adopting several strategies to maintain their market presence.Over the years, the market has witnessed a substantial number of product launches. For instance, in July 2019, KWS SAAT SE & Co. KGaA launched six new hybrid corn varieties as part of its brands, KWS and Riber, in Brazil. These varieties provide high genetic protection against insects, high yield, and tolerance against herbicides. This launch allowed the company to provide an innovative portfolio of seeds to Brazilian farmers, thereby improving their presence in Brazil.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Global Agricultural Biotechnology Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented the global agricultural biotechnology market report on the basis of application, organism type, and region:

Application Outlook (Revenue, USD Billion, 2019 2030)

Vaccine Development

Transgenic Crops & Animals

Antibiotic Development

Nutritional Supplements

Flower Culturing

Biofuels

Organism Type Outlook (Revenue, USD Billion, 2019 2030)

Plants

Conventional Techniques

Established Genetic Modification

New Breeding Techniques

Animals

Conventional Techniques

Established Genetic Modification

New Breeding Techniques

Microbes

Conventional Techniques

Established Genetic Modification

New Breeding Techniques

Looking for more? Check out our repository for all available reports on Agricultural Biotechnology in related sectors.

Quick Read Table of Contents of this Report @ Global Agricultural Biotechnology Market Size, Market Research and Industry Forecast Report, 2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

The rest is here:
Global Agricultural Biotechnology Market Size, Market Research and Industry Forecast Report, 2025 (Includes Business Impact of COVID-19) - Eurowire

The 70 rating InvestorsObserver gives to Seelos Therapeutics Inc (SEEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 89 percent of stocks in the Biotechnology industry, SEELs 70 overall rating means the stock scores better than 70 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Seelos Therapeutics Inc (SEEL) stock is trading at $1.54 as of 11:38 AM on Wednesday, Dec 30, a rise of $0.08, or 5.48% from the previous closing price of $1.46. The stock has traded between $1.41 and $1.60 so far today. Volume today is below average. So far 691,920 shares have traded compared to average volume of 2,118,378 shares.

Click Here to get the full Stock Score Report on Seelos Therapeutics Inc (SEEL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is Seelos Therapeutics Inc (SEEL) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Bioinformatics Marketis expected to reach USD 26.33 billion by 2026 from USD 7.76 billion in 2018, at a CAGR of 16.5% in the forecast period 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

To formulate the most excellent Bioinformatics market research report, an expert team follows several steps of collecting and analysing market data of the healthcare industry. Also, detailed market analysis has been performed here with the inputs from industry experts. Market definitions, segmentation, applications and value chain structure of the healthcare industry are all mentioned in the report. Businesses can acquire complete knowledge of general market conditions and tendencies with the information and data explained in this report. The credible Bioinformatics market report contains all the company profiles of the major players and brands.

Few of the major competitors currently working in the bioinformatics market areThermo Fisher Scientific (US), Illumina Inc. (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), BGI (China), Wuxi NextCODE (China), Eurofins Scientific (Luxembourg), Waters Corporation (US), Sophia Genetics (Switzerland), Partek (US), DNASTAR (US), Dassault Systmes (France), DNAnexus, Inc. (US), Genebio (Switzerland), ASEBIO (Spain), PerkinElmer Inc. (US), abm Inc.(Canada) a few among others.

Scope of the Bioinformatics Market

Bioinformatics market is segmented on the basis of countries into U.S., Canada, Mexico in North America, Brazil, Argentina, Rest of South America as a part of South America, Germany, France, U.K., Italy, Spain, Netherlands, Belgium, Russia, Turkey, Switzerland, Rest of Europe in Europe, China, Japan, India, Australia, Singapore, Thailand, Malaysia, South Korea, Indonesia, Philippines, Rest of Asia Pacific (APAC)as a part of Asia-Pacific (APAC), U.A.E, Egypt, Saudi Arabia, South Africa, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-bioinformatics-market

Market Drivers

Market Restraints

New Bioinformatics Market Development

Key Developments in the Market:

Enquire Here Get customization & check discount for report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bioinformatics-market

Report synopsis

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Link:
Global Bioinformatics Market Size And Future Prospective With Key Manufactures, Drivers & Trends 2019-2026||Agilent Technologies, Inc. (US),...

The researchoffers a comprehensive analysis of the Agricultural BiotechnologyMarket. Bringing out the complete key insights of the industry, the report aims to provide an insight into the latest trends, current market scenario, and technologies related to the market. In addition, it helps the venture capitalists to understand the revenue opportunities across different segments to make better decisions. Global Agricultural Biotechnology market provides a detailed report which covers market analyses before COVID19 & opportunities after this pandemic. With COVID-19 pandemic, many industries are transforming rapidly. The Global Agricultural Biotechnology Market is one of the major industries undergoing changes. This year many industries have vanished entirely from the market and many industries have risen.

Moreover, the government-backed schemes throughout the globe are offering many advantages to businesses. As the governing bodies are supporting the industries, it be a strong pillar to support the market growth of Agricultural Biotechnology in the upcoming decade (2020-2026). Organizations planning to move into new market segments can take the help of market indicators to draw a business plan. With the technological boom, new markets are blossoming across the globe, making it a breeding ground for new businesses.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.in4research.com/sample-request/9515

Global Agricultural Biotechnology Market 2020: Covering both the industrial and the commercial aspects of the Global Agricultural Biotechnology Market, the report encircles several crucial chapters that give the report an extra edge. The Global Agricultural Biotechnology Market report deep dives into several parts of the report that plays a crucial role in getting the holistic view of the report. The list of such crucial aspects of the report includes company profile, industry analysis, competitive dashboard, comparative analysis of the key players, regional analysis with further analysis country wise.

Global Agricultural Biotechnology Market Analysis by Key Players:

Moreover, one of the uniqueness in the report is that it also covers the country-level analysis of the regulatory scenario, technology penetration, predictive trends, and prescriptive trends. This not only gives the readers of the report the actual real-time insights but also gives country-wise analysis, that plays a vital role in decision making. The inclusion of the report is not limited to the above mention key pointers. The report also emphasizes on the market opportunities, porters five forces, and analysis of the different types of products and application of the Global Agricultural Biotechnology Market.

The report splits by major applications:

Then report analyzed by types:

Any questions or want to Customization on this report, just speak with analyst @ https://www.in4research.com/speak-to-analyst/9515

Global Agricultural Biotechnology Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Agricultural Biotechnology industry, focusing on the main regions and the main countries as Follows:

COVID-19 Impact on Agricultural Biotechnology Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Agricultural Biotechnology Market. Overall competitive landscape and market dynamics of Agricultural Biotechnology has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Agricultural Biotechnology Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Agricultural Biotechnology Market @ https://www.in4research.com/impactC19-request/9515

Table of Contents Includes Major Pointes as follows:

Read more from the original source:
Agricultural Biotechnology Market Research Report: Overview With Geographical Segmentation By Revenue With Forecast 2026 - The Haitian-Caribbean News...

Vir Biotechnology Inc. (NASDAQ:VIR) went down by -21.36% from its latest closing price compared to the recent 1-year high of $75.00. The companys stock price has collected -17.01% of loss in the last five trading sessions. Press Release reported on 11/06/20 that Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K

Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Vir Biotechnology Inc. declared the stock was a buy, while 0 rated the stock as overweight, 2 rated it as hold, and 0 as sell.

Learn from the #1 Futures Trading Education Institute in the World

Learn a direct approach to trading Futures that provides you with the techniques and the confidence you need to make consistent profits.

***For a limited time, we are offering a FREE CLASS. Dont take our word for how effective our teaching methods are see it for yourself!

Sign up today to receive free access and a guided tour through our program, PATH TO SUCCESS.

Sponsored

The average price from analysts is $54.14, which is $29.49 above the current price. VIR currently public float of 109.06M and currently shorts hold a 6.92% ratio of that float. Today, the average trading volume of VIR was 1.14M shares.

VIR stocks went down by -17.01% for the week, with a monthly drop of -37.61% and a quarterly performance of -51.56%, while its annual performance rate touched 84.45%. The volatility ratio for the week stands at 9.43% while the volatility levels for the past 30 days are set at 7.52% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is -28.59% for VIR stocks with a simple moving average of -30.02% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with BofA Securities repeating the rating for VIR by listing it as a Buy. The predicted price for VIR in the upcoming period, according to BofA Securities is $55 based on the research report published on October 05th of the current year 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR reach a price target of $54, previously predicting the price at $48. The rating they have provided for VIR stocks is Buy according to the report published on September 14th, 2020.

JP Morgan gave a rating of Neutral to VIR, setting the target price at $29 in the report published on September 11th of the current year.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.99% of loss for the given period.

Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 9.43%, as shares sank -41.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.74% lower at present.

During the last 5 trading sessions, VIR fell by -17.01%, which changed the moving average for the period of 200-days by +2.97% in comparison to the 20-day moving average, which settled at $34.83. In addition, Vir Biotechnology Inc. saw 102.86% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at VIR starting from Parrish Jay, who sale 6,944 shares at the price of $31.27 back on Nov 02. After this action, Parrish Jay now owns 222,222 shares of Vir Biotechnology Inc., valued at $217,153 using the latest closing price.

Virgin Herbert, the EVP, Research & CSO of Vir Biotechnology Inc., sale 3,805 shares at $35.04 during a trade that took place back on Oct 27, which means that Virgin Herbert is holding 23,700 shares at $133,335 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -81.10, with -42.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the companys capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.

When we switch over and look at the enterrpise to sales, we see a ratio of 119.29, with the companys debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.

Outsmart Wall Streets Top Options Traders

Its no secret that the market has provided endless opportunities to generate extremely profitable trades this past quarter. Scott Bauer, a professional trader with 25+ years of experience has already been targeting numerous triple-digit wins like these this year aloneHes actually put together a free guide that has 25 winning option strategies.

Click here to access the Options Profits Trading Guide now.

Sponsored

See original here:
The Chart for Vir Biotechnology Inc. (VIR) Is Flashing Mixed Signals - The News Heater

Two years ago, Dr. Ugur Sahin took the stage at a conference in Berlin and made a bold prediction. Speaking to a roomful of infectious disease experts, he said his company might be able to use its so-called messenger RNA technology to rapidly develop a vaccine in the event of a global pandemic.

At the time, Dr. Sahin and his company, BioNTech, were little known outside the small world of European biotechnology start-ups. BioNTech, which Dr. Sahin founded with his wife, Dr. zlem Treci, was mostly focused on cancer treatments. It had never brought a product to market. Covid-19 did not yet exist.

But his words proved prophetic.

On Monday, BioNTech and Pfizer announced that a vaccine for the coronavirus developed by Dr. Sahin and his team was more than 90 percent effective in preventing the disease among trial volunteers who had no evidence of having previously been infected. The stunning results vaulted BioNTech and Pfizer to the front of the race to find a cure for a disease that has killed more than 1.2 million people worldwide.

It could be the beginning of the end of the Covid era, Dr. Sahin said in an interview on Tuesday.

BioNTech began work on the vaccine in January, after Dr. Sahin read an article in the medical journal The Lancet that left him convinced that the coronavirus, at the time spreading quickly in parts of China, would explode into a full-blown pandemic. Scientists at the company, based in Mainz, Germany, canceled vacations and set to work on what they called Project Lightspeed.

There are not too many companies on the planet which have the capacity and the competence to do it so fast as we can do it, Dr. Sahin said in an interview last month. So it felt not like an opportunity, but a duty to do it, because I realized we could be among the first coming up with a vaccine.

After BioNTech had identified several promising vaccine candidates, Dr. Sahin concluded that the company would need help to rapidly test them, win approval from regulators and bring the best candidate to market. BioNTech and Pfizer had been working together on a flu vaccine since 2018, and in March, they agreed to collaborate on a coronavirus vaccine.

Since then, Dr. Sahin, who is Turkish, has developed a friendship with Albert Bourla, the Greek chief executive of Pfizer. The pair said in recent interviews that they had bonded over their shared backgrounds as scientists and immigrants.

We realized that he is from Greece, and that Im from Turkey, Dr. Sahin said, without mentioning their native countries long-running antagonism. It was very personal from the very beginning.

Dr. Sahin, 55, was born in Iskenderun, Turkey. When he was 4, his family moved to Cologne, Germany, where his parents worked at a Ford factory. He grew up wanting to be a doctor, and became a physician at the University of Cologne. In 1993, he earned a doctorate from the university for his work on immunotherapy in tumor cells.

Early in his career, he met Dr. Treci. She had early hopes to become a nun and ultimately wound up studying medicine. Dr. Treci, now 53 and the chief medical officer of BioNTech, was born in Germany, the daughter of a Turkish physician who immigrated from Istanbul. On the day they were married, Dr. Sahin and Dr. Treci returned to the lab after the ceremony.

The pair were initially focused on research and teaching, including at the University of Zurich, where Dr. Sahin worked in the lab of Rolf Zinkernagel, who won the 1996 Nobel Prize in medicine.

In 2001, Dr. Sahin and Dr. Treci founded Ganymed Pharmaceuticals, which developed drugs to treat cancer using monoclonal antibodies.

After several years they founded BioNTech as well, looking to use a wider range of technologies, including messenger RNA, to treat cancer. We want to build a large European pharmaceutical company, Dr. Sahin said in an interview with the Wiesbaden Courier, a local paper.

Even before the pandemic, BioNTech was gaining momentum. The company raised hundreds of millions of dollars and now has more than 1,800 people on staff, with offices in Berlin, other German cities and Cambridge, Mass. In 2018, it began its partnership with Pfizer. Last year, the Bill & Melinda Gates Foundation invested $55 million to fund its work treating H.I.V. and tuberculosis. Also in 2019, Dr. Sahin was awarded the Mustafa Prize, a biennial Iranian prize for Muslims in science and technology.

Dr. Sahin and Dr. Treci sold Ganymed for $1.4 billion in 2016. Last year, BioNTech sold shares to the public; in recent months, its market value has soared past $21 billion, making the couple among the richest in Germany.

The two billionaires live with their teenage daughter in a modest apartment near their office. They ride bicycles to work. They do not own a car.

Ugur is a very, very unique individual, Mr. Bourla, Pfizers chief executive, said in the interview last month. He cares only about science. Discussing business is not his cup of tea. He doesnt like it at all. Hes a scientist and a man of principles. I trust him 100 percent.

In Germany, where immigration continues to be a fractious issue, the success of two scientists of Turkish descent was cause for celebration.

With this couple, Germany has a shining example of successful integration, wrote the conservative-business site Focus.

A member of Parliament, Johannes Vogel, wrote on Twitter that if it was up to the far-right Alternative for Germany party, there would be no #BioNTech of Germany with zlem Treci & Ugur Sahin at the top.

If it were up to critics of capitalism and globalization, he added, there would be no cooperation with Pfizer. But that makes us strong: immigration country, market economy & open society!

Dr. Sahin has had little time for politics this year. BioNTech has been so busy developing a vaccine that the company has not finalized the financial details of its partnership agreement with Pfizer.

Trust and personal relationship is so important in such business, because everything is going so fast, Dr. Sahin said. We still have a term sheet and not yet a final contract on many things.

Dr. Sahin said he and Dr. Treci learned about efficacy data on Sunday night and marked the moment by brewing Turkish tea at home. We celebrated, of course, he said. It was a relief.

Christopher F. Schuetze contributed reporting from Berlin.

Here is the original post:
The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19 - The New York Times

PDS Biotech to participate in Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by Alliance Global Partners Monday November 2, 2020

PDS Biotech to announce Third Quarter 2020 Financial Results Wednesday November 11, 2020 and host a conference call on Thursday, November 12, 2020

FLORHAM PARK, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that the Company will be featured in a live webinar, Grand Rounds: A Webinar in Biotech and Specialty Pharma, hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners, on Monday, November 2nd at 10:30 am Eastern Time.

Grand Rounds Webinar Presentation Information: Date: Monday, November 2, 2020Time: 10:30 am Eastern TimeWebcast link: Click Here

Conference Call and Webcast for Third Quarter 2020 Financial ResultsThe Company also announced that it plans to report financial results for the third quarter ended September 30, 2020 on Wednesday November 11, 2020, after the close of the market. On Thursday, November 12, 2020, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am Eastern Time on Thursday, November 12, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13712632.

Story continues

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Jacob GoldbergerCG CapitalPhone: +1 (404) 736-3841Email: jacob@cg.capital

Read the original post:
PDS Biotechnology Announces Feature in Grand Rounds Webinar hosted by Alliance Global Partners and Conference Call and Webcast for Third Quarter 2020...